منابع مشابه
Melphalan therapy of polycythemia vera.
Twenty-seven patients with p. vera and adverse hematologic effects were whose proliferative disease required the infrequent. To date one patient has desuppression of bone marrow function veloped refractory anemia and evidence were treated with melphalan for periods of myelofibrosis. Four patients have deof 20 to 72 months. The response was veloped acute leukemia but none of these rated as good ...
متن کاملPipobroman therapy of polycythemia vera.
Between 1971 and 1981, 74 patients with polycythemia vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen. Complete remission was achieved in 51 of 54 previously untreated patients (94.4%) and in 17 of 20 patients (85%) previously treated wih radioactive phosphorus (32 p) and busulfan. The earliest modifications were noted on day 16, and on the average, bl...
متن کامل[Therapy of polycythemia vera with myleran].
By NIEL WALD, TAKASHI HOSHINO AND MARY E. SEARS MYLERAN#{176} was developed in the course of a study of the tumor-inhibiting effect of various sulfonic acid esters by Haddow and Timmis.1 Because of the neutropenia, unaccompanied by other side effects, which was observed during its ineffective clinical trial in vaniotis types of cancer in man, Myieran was employed in the treatment of chronic gra...
متن کاملTreatment of polycythemia vera.
BACKGROUND AND OBJECTIVE Current guidelines for the management of patients with polycythemia vera (PV) derive from a few clinical trials and several uncontrolled clinical studies. The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient. METHODS The authors have been working in this field contributing origina...
متن کاملPathogenesis of polycythemia vera.
BACKGROUND AND OBJECTIVE Polycythemia vera (PV) is an acquired clonal myeloproliferative disorder characterized by increased production of mature red cells. We still lack a molecular target responsible for this disorder; however, recent investigations have focused on a number of molecules involved in signal transduction pathways mediated by erythropoietin (Epo) and other growth factors. Here we...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 1970
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v36.1.70.70